Vir Biotechnology, Inc. (NASDAQ:VIR) CEO Sells $474,286.40 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) CEO Backer Marianne De sold 79,712 shares of the company’s stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $5.95, for a total transaction of $474,286.40. Following the completion of the sale, the chief executive officer now owns 769,505 shares of the company’s stock, valued at $4,578,554.75. This represents a 9.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Vir Biotechnology Price Performance

NASDAQ:VIR opened at $5.58 on Friday. Vir Biotechnology, Inc. has a one year low of $5.49 and a one year high of $14.45. The company has a fifty day moving average price of $8.36 and a 200 day moving average price of $8.29. The stock has a market cap of $765.26 million, a P/E ratio of -1.42 and a beta of 1.14.

Vir Biotechnology (NASDAQ:VIR) last released its earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.09. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The business had revenue of $12.37 million during the quarter, compared to analysts’ expectations of $8.14 million. As a group, equities research analysts anticipate that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Institutional Trading of Vir Biotechnology

Several institutional investors have recently modified their holdings of VIR. State of Tennessee Department of Treasury lifted its position in Vir Biotechnology by 3.2% in the fourth quarter. State of Tennessee Department of Treasury now owns 39,268 shares of the company’s stock worth $288,000 after purchasing an additional 1,227 shares during the period. Rhumbline Advisers raised its stake in shares of Vir Biotechnology by 0.5% in the 4th quarter. Rhumbline Advisers now owns 236,681 shares of the company’s stock valued at $1,737,000 after buying an additional 1,288 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Vir Biotechnology by 31.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company’s stock worth $61,000 after acquiring an additional 1,999 shares during the period. Teacher Retirement System of Texas boosted its position in shares of Vir Biotechnology by 10.7% during the 4th quarter. Teacher Retirement System of Texas now owns 26,440 shares of the company’s stock valued at $194,000 after acquiring an additional 2,556 shares in the last quarter. Finally, Invesco Ltd. increased its stake in Vir Biotechnology by 0.6% in the fourth quarter. Invesco Ltd. now owns 398,772 shares of the company’s stock valued at $2,927,000 after acquiring an additional 2,574 shares during the period. Institutional investors and hedge funds own 65.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on VIR. JPMorgan Chase & Co. upped their price target on Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a research note on Thursday, January 9th. Morgan Stanley raised Vir Biotechnology from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $10.00 to $20.00 in a research report on Thursday, January 9th. Barclays boosted their price objective on shares of Vir Biotechnology from $26.00 to $31.00 and gave the stock an “overweight” rating in a research note on Friday, February 28th. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 target price on shares of Vir Biotechnology in a research note on Thursday, February 27th. Finally, Leerink Partners boosted their target price on shares of Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, Vir Biotechnology presently has a consensus rating of “Moderate Buy” and an average target price of $35.67.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).